record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
Buell et al. 2021 Acta Neuropathologica Communications
authors
reviewer:will-blair
TP53 wild-type, PPM1D-mutant DIPGs show heightened sensitivity to MDM2 antagonists, indicating retained p53 pathway vulnerability despite PPM1D-mediated Wip1 overexpression.
vs_e3e1dbbe670fc6b5 · manual_curation
outgoing
vf_97bb0892807d6ac9MDM2 antagonist efficacy in PPM1D-mutant cases identifies p53-pathway-based therapy for ACVR1 wt DIPG
events
vev_83609cd46f09a264finding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_639e6bc90819afb1finding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.